Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.110
Filter
1.
Anal Chim Acta ; 1310: 342663, 2024 Jun 29.
Article in English | MEDLINE | ID: mdl-38811130

ABSTRACT

The diagnosis of malignant melanoma, often an inconspicuous but highly aggressive tumor, is most commonly done by histological examination, while additional diagnostic methods on the level of elements and molecules are constantly being developed. Several studies confirmed differences in the chemical composition of healthy and tumor tissue. Our study presents the potential of the LIBS (Laser-Induced-Breakdown Spectroscopy) technique as a diagnostic tool in malignant melanoma (MM) based on the quantitative changes in elemental composition in cancerous tissue. Our patient group included 17 samples of various types of malignant melanoma and one sample of healthy skin tissue as a control. To achieve a clear perception of results, we have selected two biogenic elements (calcium and magnesium), which showed a dissimilar distribution in cancerous tissue from its healthy surroundings. Moreover, we observed indications of different concentrations of these elements in different subtypes of malignant melanoma, a hypothesis that requires confirmation in a more extensive sample set. The information provided by the LIBS Imaging method could potentially be helpful not only in the diagnostics of tumor tissue but also be beneficial in broadening the knowledge about the tumor itself.


Subject(s)
Lasers , Magnesium , Melanoma , Skin Neoplasms , Spectrum Analysis , Humans , Melanoma/pathology , Melanoma/diagnostic imaging , Melanoma/diagnosis , Melanoma/chemistry , Spectrum Analysis/methods , Magnesium/analysis , Skin Neoplasms/pathology , Skin Neoplasms/diagnostic imaging , Calcium/analysis
2.
Biosens Bioelectron ; 239: 115601, 2023 Nov 01.
Article in English | MEDLINE | ID: mdl-37633000

ABSTRACT

Effective and convenient detection of melanoma cells with high sensitivity is essential to identify malignant melanoma in its early stage. However, the existing detection methods, such as immunohistochemical analysis, are too complicated and time-consuming to realize the convenient in vivo and in situ detection. Herein, a near infrared responsive photoelectrochemical (PEC) immunosensor is proposed with plasmonic Au nanoparticles-photonic TiO2 nanocaves (Au/TiO2 NCs) as photon harvest and conversion transducer and antibody as cell recognition unit. The micro-antibody/Au/TiO2 NCs photoelectrode can easily in vivo distinguish melanoma cells and can realize sensitive detection of melanoma cells in short time of 1 min with a lowest limit of detection of 2 cell mL-1. The PEC immunosensor strategy not only allows us to pioneeringly implement sensitive in vivo bio-detection, but also opens up a new avenue for rational design of cell recognition units and micro-electrode for universal and reliable bio-detections.


Subject(s)
Biosensing Techniques , Immunoassay , Melanoma , Immunoassay/methods , Spectroscopy, Near-Infrared/methods , Photochemistry/methods , Melanoma/chemistry , Melanoma/diagnosis , Gold , Metal Nanoparticles , Humans , Animals , Mice , Cell Line, Tumor , Biosensing Techniques/methods
3.
Int J Mol Sci ; 24(9)2023 May 05.
Article in English | MEDLINE | ID: mdl-37176019

ABSTRACT

The melanin pigments eumelanin (EM) and pheomelanin (PM), which are dark brown to black and yellow to reddish-brown, respectively, are widely found among vertebrates. They are produced in melanocytes in the epidermis, hair follicles, the choroid, the iris, the inner ear, and other tissues. The diversity of colors in animals is mainly caused by the quantity and quality of their melanin, such as by the ratios of EM versus PM. We have developed micro-analytical methods to simultaneously measure EM and PM and used these to study the biochemical and genetic fundamentals of pigmentation. The photoreactivity of melanin has become a major focus of research because of the postulated relevance of EM and PM for the risk of UVA-induced melanoma. Our biochemical methods have found application in many clinical studies on genetic conditions associated with alterations in pigmentation. Recently, besides chemical degradative methods, other methods have been developed for the characterization of melanin, and these are also discussed here.


Subject(s)
Melanins , Melanoma , Animals , Melanins/analysis , Melanocytes , Pigmentation , Epidermis , Melanoma/chemistry
4.
Spectrochim Acta A Mol Biomol Spectrosc ; 286: 122029, 2023 Feb 05.
Article in English | MEDLINE | ID: mdl-36323090

ABSTRACT

Melanoma is an aggressive and metastatic skin cancer caused by genetic mutations in melanocytes, and its incidence is increasing year by year. Understanding the gene mutation information of melanoma cases is very important for its precise treatment. The current diagnostic methods for melanoma include radiological, pharmacological, histological, cytological and molecular techniques, but the gold standard for diagnosis is still pathological biopsy, which is time consuming and destructive. Raman spectroscopy is a rapid, sensitive and nondestructive detection method. In this study, a total of 20,000 Surface-enhanced Raman scattering (SERS) spectra of melanocytes and melanoma cells were collected using a positively charged gold nanoparticles planar solid SERS substrate, and a classification network system based on convolutional neural networks (CNN) was constructed to achieve the classification of melanocytes and melanoma cells, wild-type and mutant melanoma cells and their drug resistance. Among them, the classification accuracy of melanocytes and melanoma cells was over 98%. Raman spectral differences between melanocytes and melanoma cells were analyzed and compared, and the response of cells to antitumor drugs were also evaluated. The results showed that Raman spectroscopy provided a basis for the medication of melanoma, and SERS spectra combined with CNN classification model realized classification of melanoma, which is of great significance for rapid diagnosis and identification of melanoma.


Subject(s)
Deep Learning , Melanoma , Metal Nanoparticles , Humans , Spectrum Analysis, Raman/methods , Gold , Metal Nanoparticles/chemistry , Melanoma/diagnosis , Melanoma/chemistry , Melanoma/pathology
5.
Opt Express ; 30(18): 31852-31862, 2022 Aug 29.
Article in English | MEDLINE | ID: mdl-36242259

ABSTRACT

Pump-probe microscopy of melanin in tumors has been proposed to improve diagnosis of malignant melanoma, based on the hypothesis that aggressive cancers disaggregate melanin structure. However, measured signals of melanin are complex superpositions of multiple nonlinear processes, which makes interpretation challenging. Polarization control during measurement and data fitting are used to decompose signals of melanin into their underlying molecular mechanisms. We then identify the molecular mechanisms that are most susceptible to melanin disaggregation and derive false-coloring schemes to highlight these processes in biological tissue. We demonstrate that false-colored images of a small set of melanoma tumors correlate with clinical concern. More generally, our systematic approach of decomposing pump-probe signals can be applied to a multitude of different samples.


Subject(s)
Melanoma , Skin Neoplasms , Humans , Melanins/chemistry , Melanoma/chemistry , Melanoma/diagnostic imaging , Microscopy/methods , Skin Neoplasms/pathology
6.
Am J Dermatopathol ; 44(1): 33-36, 2022 Jan 01.
Article in English | MEDLINE | ID: mdl-33201009

ABSTRACT

ABSTRACT: The presence of neoplastic melanocytes within the eccrine apparatus into the reticular dermis and/or subcutaneous tissue is extremely rare. The staging of syringotropic melanomas and their biological behavior are still controversial. We present 6 new cases of syringotropic melanoma and their main histopathologic features; review the previous literature; and discuss about the origin, staging, and prognosis of this rare variant of melanoma.


Subject(s)
Melanocytes/pathology , Melanoma/pathology , Skin Neoplasms/pathology , Sweat Glands/pathology , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Biopsy , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Male , Melanocytes/chemistry , Melanoma/chemistry , Melanoma/surgery , Middle Aged , Predictive Value of Tests , Skin Neoplasms/chemistry , Skin Neoplasms/surgery , Sweat Glands/chemistry , Sweat Glands/surgery , Treatment Outcome
7.
Diagn Pathol ; 16(1): 78, 2021 Aug 28.
Article in English | MEDLINE | ID: mdl-34454530

ABSTRACT

BACKGROUND: Melanoma is a highly malignant tumor with diverse histopathological morphology and frequent aberrant expression of immunohistochemical markers. An occasionally reported phenomenon is the abnormal expression of neuroendocrine markers. Awareness of this situation is essential because such tumors need to be differentiated from neuroendocrine tumors because of their significant therapeutic and prognostic implications. METHODS: We retrospectively analyzed the expression of chromogranin A (CgA), synaptophysin (Syn) and CD56 as neuroendocrine markers in 308 cases with melanomas. Kaplan-Meier curves and Cox regression analyses were used for overall survival (OS) and progression-free survival (PFS) evaluation and comparison between neuroendocrine markers expression status in all melanoma cases or stage I-II cases. RESULTS: The expression of neuroendocrine markers in melanomas is not uncommon. CgA was positive in 6/304 (2.0%) cases, Syn in 26/304 (8.6%), and CD56 in 56/189 (29.6%). None of the cases co-expressed all the three markers. Focal or weak expression of at least one neuroendocrine marker was identified in 70/188 (37.2%) cases. The expression of CgA was correlated with age (p = 0.019), while the positive expression of Syn and CD56 showed borderline significance (p = 0.078 and 0.083, respectively), but not for any neuroendocrine marker expression. The expression of any neuroendocrine marker showed borderline significance with staging (p = 0.066). The expression of CgA, Syn, CD56, or any neuroendocrine marker did not correlate with clinicopathological features including sex, specimen type, origin, location, and histology subtype. Survival analyses revealed that the expression of neuroendocrine markers was not associated with OS or PFS. CONCLUSIONS: Our study confirms that neuroendocrine marker expression is a common phenomenon in melanomas, but it has no prognostic significance. Nevertheless, awareness can avoid misdiagnosis in cases of melanomas with unusual morphology and immunophenotypes.


Subject(s)
Biomarkers, Tumor/analysis , Immunohistochemistry , Melanoma/chemistry , Neuroendocrine Tumors/chemistry , Skin Neoplasms/chemistry , Adolescent , Adult , Aged , Aged, 80 and over , CD56 Antigen/analysis , Child , Chromogranin A/analysis , Diagnostic Errors , Female , Humans , Male , Melanoma/mortality , Melanoma/pathology , Melanoma/therapy , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Progression-Free Survival , Retrospective Studies , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Synaptophysin/analysis , Time Factors , Young Adult
8.
Science ; 372(6547)2021 06 11.
Article in English | MEDLINE | ID: mdl-34112666

ABSTRACT

Next-generation tissue-based biomarkers for immunotherapy will likely include the simultaneous analysis of multiple cell types and their spatial interactions, as well as distinct expression patterns of immunoregulatory molecules. Here, we introduce a comprehensive platform for multispectral imaging and mapping of multiple parameters in tumor tissue sections with high-fidelity single-cell resolution. Image analysis and data handling components were drawn from the field of astronomy. Using this "AstroPath" whole-slide platform and only six markers, we identified key features in pretreatment melanoma specimens that predicted response to anti-programmed cell death-1 (PD-1)-based therapy, including CD163+PD-L1- myeloid cells and CD8+FoxP3+PD-1low/mid T cells. These features were combined to stratify long-term survival after anti-PD-1 blockade. This signature was validated in an independent cohort of patients with melanoma from a different institution.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Biomarkers, Tumor/analysis , Fluorescent Antibody Technique , Melanoma/drug therapy , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Adult , Aged , Aged, 80 and over , Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , B7-H1 Antigen/analysis , CD8 Antigens/analysis , Female , Forkhead Transcription Factors/analysis , Humans , Immune Checkpoint Proteins/analysis , Macrophages/chemistry , Male , Melanoma/chemistry , Melanoma/immunology , Melanoma/pathology , Middle Aged , Prognosis , Programmed Cell Death 1 Receptor/analysis , Progression-Free Survival , Receptors, Cell Surface/analysis , SOXE Transcription Factors/analysis , Single-Cell Analysis , T-Lymphocyte Subsets/chemistry , T-Lymphocyte Subsets/immunology , Treatment Outcome , Tumor Microenvironment
9.
Appl Opt ; 60(13): 3772-3778, 2021 May 01.
Article in English | MEDLINE | ID: mdl-33983310

ABSTRACT

Melanoma is a common, highly fatal skin cancer. Photoacoustic imaging can achieve highly sensitive and high-contrast detection of melanin molecules in tissues, also inheriting the high penetration depth and high spatial resolution characteristics of ultrasound imaging, thus it is a very promising non-invasive diagnostic tool for early melanoma. In this work, we built an acoustic-resolution-based photoacoustic microscopy system, using 1064 nm/532 nm pulsed light to observe melanoma in the back of a mouse with simultaneous photoacoustic/ultrasound imaging. Through the fusion of multi-modal images, accurate positioning of melanoma and its surrounding normal tissues were realized. This work will further promote the application of photoacoustic imaging in the clinical diagnosis of early melanoma.


Subject(s)
Melanoma/diagnostic imaging , Multimodal Imaging/methods , Photoacoustic Techniques/methods , Skin Neoplasms/diagnostic imaging , Ultrasonography/methods , Animals , Early Detection of Cancer/methods , Melanins/analysis , Melanoma/chemistry , Melanoma/pathology , Metals , Mice , Mice, Inbred C57BL , Phantoms, Imaging , Skin Neoplasms/chemistry , Skin Neoplasms/pathology
10.
Methods Mol Biol ; 2265: 289-304, 2021.
Article in English | MEDLINE | ID: mdl-33704723

ABSTRACT

Cells release extracellular vesicles (EVs) that can be detected both in vivo and in cell culture medium. Among EVs, exosomes are 50-150 nm vesicles that are systematically packaged into multivesicular bodies for release into the external environment. In cancer, these intentionally packaged exosomes carry a payload of proteins such as RNAs and surface receptors that facilitate the reprogramming of proximal cells to assemble a protumor microenvironment. Exosomes have been implicated as an important intermediary extracellular communication pathway between cells, including in melanoma. Human melanoma-derived exosomes (HMEX) have been demonstrated to modulate the extracellular environment and inhibit immune cell activation. There are many methods to isolate and enrich for exosomes and the method applied can impact yield and purity of the isolates. In this chapter we describe the REIUS (rapid exosome isolation using ultrafiltration and size exclusion chromatography) method to isolate HMEX from melanoma cell cultures and then demonstrate their enrichment using molecular and microscopic approaches.


Subject(s)
Exosomes/chemistry , Melanoma/chemistry , Cell Line, Tumor , Chromatography, Gel , Humans , Ultrafiltration
11.
Cancer Med ; 10(6): 1955-1963, 2021 03.
Article in English | MEDLINE | ID: mdl-33620160

ABSTRACT

PURPOSE: To date there has not been an extensive analysis of the outcomes of biomarker use in oncology. METHODS: Data were pooled across four indications in oncology drawing upon trial outcomes from www.clinicaltrials.gov: breast cancer, non-small cell lung cancer (NSCLC), melanoma and colorectal cancer from 1998 to 2017. We compared the likelihood drugs would progress through the stages of clinical trial testing to approval based on biomarker status. This was done with multi-state Markov models, tools that describe the stochastic process in which subjects move among a finite number of states. RESULTS: Over 10000 trials were screened, which yielded 745 drugs. The inclusion of biomarker status as a covariate significantly improved the fit of the Markov model in describing the drug trajectories through clinical trial testing stages. Hazard ratios based on the Markov models revealed the likelihood of drug approval with biomarkers having nearly a fivefold increase for all indications combined. A 12, 8 and 7-fold hazard ratio was observed for breast cancer, melanoma and NSCLC, respectively. Markov models with exploratory biomarkers outperformed Markov models with no biomarkers. CONCLUSION: This is the first systematic statistical evidence that biomarkers clearly increase clinical trial success rates in three different indications in oncology. Also, exploratory biomarkers, long before they are properly validated, appear to improve success rates in oncology. This supports early and aggressive adoption of biomarkers in oncology clinical trials.


Subject(s)
Antineoplastic Agents/therapeutic use , Biomarkers, Tumor , Clinical Trials as Topic , Drug Approval , Markov Chains , Neoplasms/drug therapy , Biomarkers, Tumor/classification , Biomarkers, Tumor/genetics , Breast Neoplasms/chemistry , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Carcinoma, Non-Small-Cell Lung/chemistry , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Clinical Trials as Topic/classification , Clinical Trials as Topic/statistics & numerical data , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Colorectal Neoplasms/chemistry , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/genetics , Databases, Factual/statistics & numerical data , Drug Approval/methods , Drug Approval/statistics & numerical data , Female , Genetic Markers , Humans , Lung Neoplasms/chemistry , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Male , Medical Oncology , Melanoma/chemistry , Melanoma/drug therapy , Melanoma/genetics , Neoplasms/chemistry , Neoplasms/genetics , Risk , Skin Neoplasms/chemistry , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics , Stochastic Processes , Time Factors , Treatment Failure
12.
J Extracell Vesicles ; 10(4): e12063, 2021 02.
Article in English | MEDLINE | ID: mdl-33613873

ABSTRACT

Molecular profiling of small extracellular vesicles (sEV) isolated from plasma of cancer patients emerges as promising strategy for biomarkers discovery. We investigated the proteomic profiles of sEV immunoselected using anti-CSPG4 antibodies from 15 melanoma patients' plasma. The proteomes of sEV separated into melanoma cell-derived (MTEX) and non-malignant cell-derived (NMTEX) were compared using high-resolution mass spectrometry. Paired analysis identified the MTEX-associated profile of 16 proteins that discriminated MTEX from NMETEX. We also identified the MTEX profile that discriminated between seven patients with no evidence of melanoma (NED) after therapy and eight with progressive disease (PD). Among 75 MTEX proteins overexpressed in PD patients, PDCD6IP (ALIX) had the highest discriminating value, while CNTN1 (contactin-1) was upregulated only in MTEX of NED patients. This is the first report documenting that proteomes of tumour-derived sEV in patients' plasma discriminate cancer from non-cancer and identify proteins with potential to serve as prognostic biomarkers in melanoma.


Subject(s)
Exosomes/metabolism , Extracellular Vesicles/metabolism , Melanoma/metabolism , Plasma/metabolism , Proteome/metabolism , Adult , Aged , Biomarkers, Tumor/blood , Chondroitin Sulfate Proteoglycans/immunology , Chondroitin Sulfate Proteoglycans/metabolism , Contactin 1/metabolism , Disease Progression , Exosomes/chemistry , Extracellular Vesicles/chemistry , Female , Humans , Male , Mass Spectrometry , Melanoma/chemistry , Membrane Proteins/immunology , Membrane Proteins/metabolism , Middle Aged , Plasma/chemistry , Proteins/metabolism
13.
J Am Soc Mass Spectrom ; 32(3): 653-660, 2021 Mar 03.
Article in English | MEDLINE | ID: mdl-33507077

ABSTRACT

Nanospray desorption electrospray ionization mass spectrometry is an ambient ionization technique that is capable of mapping proteins in tissue sections. However, high-abundant molecules or isobaric interference in biological samples hampers its broad applications in probing low-abundant proteins. To address this challenge, herein we demonstrated an integrated module that coupled pneumatic-assisted nanospray desorption electrospray ionization mass spectrometry with high-field asymmetric ion mobility spectrometry. Using this module to analyze mouse brain sections, the protein coverage was significantly increased. This improvement allowed the mapping of low-abundant proteins in tissue sections with a 5 µm spatial resolution enabled by computationally assisted fusion with optical microscopic images. Moreover, the module was successfully applied to characterize melanoma in skin tissues based on the enhanced protein profiles. The results suggested that this integrating module will be potentially applied to discover novel proteins in cancers.


Subject(s)
Ion Mobility Spectrometry/instrumentation , Neoplasms/diagnosis , Proteins/analysis , Spectrometry, Mass, Electrospray Ionization/instrumentation , Animals , Humans , Melanoma/chemistry , Melanoma/diagnosis , Mice , Molecular Imaging/methods , Neoplasms/chemistry , Skin Neoplasms/chemistry , Skin Neoplasms/diagnosis
17.
Am J Dermatopathol ; 43(4): 252-258, 2021 Apr 01.
Article in English | MEDLINE | ID: mdl-33201012

ABSTRACT

BACKGROUND: Atypical intraepidermal melanocytic proliferation (AIMP) is a general term assigned to melanocytic proliferations of uncertain biological potential when a definitive histopathological diagnosis cannot be achieved. There are few data available describing the possibility of malignancy of AIMP, or ways to further define diagnosis. OBJECTIVE: To determine the rate of diagnostic change of AIMP to melanoma or melanoma in situ (MIS) after conventional excision. In addition, to determine the role of immunohistochemistry (IHC) in defining AIMP biopsies. METHODS: Retrospective cross-sectional, single-center review of biopsies with a diagnosis of AIMP with a follow-up conventional excision from 2012-2016 was performed. In a separate analysis, a search was performed for AIMP biopsied lesions in which IHC was subsequently performed. RESULTS: The rate of diagnostic change of AIMP to MIS was 4.8% (8/167) after excision. Punch biopsy was a risk factor for diagnostic change to MIS (odds ratio 12.94, confidence interval 2.56-65.38, P = 0.008). The rate of diagnostic change of AIMP biopsies after examining with IHC was 21.3% (34/160) to MIS and 4.4% (7/160) to melanoma. CONCLUSION: The possibility of malignancy of AIMP lesions must be taken into consideration when counseling patients and when planning treatment options. IHC is a useful tool and should be used in the evaluation of AIMP specimens.


Subject(s)
Cell Proliferation , Melanocytes/pathology , Melanoma/pathology , Skin Neoplasms/pathology , Terminology as Topic , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Biopsy , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Immunohistochemistry , Infant , Infant, Newborn , Male , Melanocytes/chemistry , Melanoma/chemistry , Melanoma/classification , Melanoma/surgery , Middle Aged , Predictive Value of Tests , Retrospective Studies , Skin Neoplasms/chemistry , Skin Neoplasms/classification , Skin Neoplasms/surgery , Young Adult
18.
Sci Rep ; 10(1): 18336, 2020 10 27.
Article in English | MEDLINE | ID: mdl-33110110

ABSTRACT

Immune cell infiltrates in melanoma have important prognostic value. Gene expression analysis may simultaneously quantify numbers and function of multiple immune cell subtypes in formalin-fixed paraffin-embedded (FFPE) tissues. Prior studies report single gene expression can represent individual immune cell subtypes, but this has not been shown in FFPE melanomas. We hypothesized that gene expression profiling of human melanomas using a new RNA expression technology in FFPE tissue would correlate with the same immune cells identified by immunohistochemistry (IHC). This retrospective study included melanoma specimens analyzed by IHC on tumor tissue microarray (TMA) cores and by gene expression profiling with EdgeSeq Immuno-Oncology Assay using qNPA technology on the corresponding tumors. Standardized gene expression levels were analyzed relative to enumerated cells by IHC using Spearman rank test to calculate r-values. Multivariate analysis was performed by Kruskal-Wallis test. 119 melanoma specimens had both IHC and gene expression information available. There were significant associations between the level of gene expression and its quantified IHC cell marker for CD45+, CD3+, CD8+, CD4+, and CD20+ cells (all p < 0.001). There were also significant associations with exhaustion markers FoxP3+, PD-1+, and PD-L1+ (all p ≤ 0.0001). This new qNPA technology is useful to quantify intratumoral immune cells on FFPE specimens through RNA gene expression in metastatic melanoma. As previous studies have shown on other solid human tumors, we also confirm that the expression level of a single gene may be used to represent a single IHC immune cell marker in melanoma.


Subject(s)
Gene Expression Profiling/methods , Melanoma/metabolism , T-Lymphocyte Subsets/metabolism , Formaldehyde , Humans , Immunity, Cellular , Melanoma/chemistry , Melanoma/immunology , Paraffin Embedding , Retrospective Studies , Tissue Array Analysis , Transcriptome , Tumor Microenvironment/immunology
19.
PLoS One ; 15(9): e0238591, 2020.
Article in English | MEDLINE | ID: mdl-32886718

ABSTRACT

Extracellular vesicles (EVs), are important for intercellular communication in both physiological and pathological processes. To explore the potential of cancer derived EVs as disease biomarkers for diagnosis, monitoring, and treatment decision, it is necessary to thoroughly characterize their biomolecular content. The aim of the study was to characterize and compare the protein content of EVs derived from three different cancer cell lines in search of a specific molecular signature, with emphasis on proteins related to the carcinogenic process. Oral squamous cell carcinoma (OSCC), pancreatic ductal adenocarcinoma (PDAC) and melanoma brain metastasis cell lines were cultured in CELLine AD1000 flasks. EVs were isolated by ultrafiltration and size-exclusion chromatography and characterized. Next, the isolated EVs underwent liquid chromatography-mass spectrometry (LC-MS) analysis for protein identification. Functional enrichment analysis was performed for a more general overview of the biological processes involved. More than 600 different proteins were identified in EVs from each particular cell line. Here, 14%, 10%, and 24% of the identified proteins were unique in OSCC, PDAC, and melanoma vesicles, respectively. A specific protein profile was discovered for each cell line, e.g., EGFR in OSCC, Muc5AC in PDAC, and FN1 in melanoma vesicles. Nevertheless, 25% of all the identified proteins were common to all cell lines. Functional enrichment analysis linked the proteins in each data set to biological processes such as "biological adhesion", "cell motility", and "cellular component biogenesis". EV proteomics discovered cancer-specific protein profiles, with proteins involved in processes promoting tumor progression. In addition, the biological processes associated to the melanoma-derived EVs were distinct from the ones linked to the EVs isolated from OSCC and PDAC. The malignancy specific biomolecular cues in EVs may have potential applications as diagnostic biomarkers and in therapy.


Subject(s)
Extracellular Vesicles/pathology , Neoplasms/pathology , Proteins/analysis , Biomarkers, Tumor/analysis , Brain Neoplasms/chemistry , Brain Neoplasms/diagnosis , Brain Neoplasms/pathology , Brain Neoplasms/secondary , Carcinoma, Pancreatic Ductal/chemistry , Carcinoma, Pancreatic Ductal/diagnosis , Carcinoma, Pancreatic Ductal/pathology , Carcinoma, Squamous Cell/chemistry , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Extracellular Vesicles/chemistry , Humans , Mass Spectrometry , Melanoma/chemistry , Melanoma/diagnosis , Melanoma/pathology , Mouth Neoplasms/chemistry , Mouth Neoplasms/diagnosis , Mouth Neoplasms/pathology , Neoplasms/chemistry , Neoplasms/diagnosis , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/pathology , Proteomics
20.
Am J Dermatopathol ; 42(12): 977-980, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32956096

ABSTRACT

Merkel cell carcinoma (MCC) is an uncommon, but aggressive neoplasm with neuroendocrine differentiation that occurs on sun-damaged skin of the elderly. Because its clinical presentation is usually nonspecific, the diagnosis is often made after histopathologic evaluation. Most cases are intradermal. Epidermal involvement is uncommon, whereas MCC limited to the epidermis is extremely rare. Here, we describe a case of MCC in an 88-year-old man with an extraordinary histopathologic presentation, namely nested intraepidermal proliferation of neoplastic cells highly resembling melanoma in situ.


Subject(s)
Carcinoma, Merkel Cell/pathology , Cell Differentiation , Cell Proliferation , Melanoma/pathology , Skin Neoplasms/pathology , Aged, 80 and over , Biomarkers, Tumor/analysis , Biopsy , Carcinoma, Merkel Cell/chemistry , Diagnosis, Differential , Humans , Immunohistochemistry , Male , Melanoma/chemistry , Predictive Value of Tests , Skin Neoplasms/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...